(Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced pre-clinical data which indicates that DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), demonstrated superiority in weight loss, retention of lean body mass, and lipid-lowering effects compared to survodutide, in pre-clinical models
A single 50 mg vial lasts roughly 10 to 20 days at these subcutaneous doses
[PMID: 2387664] PubMed record related to this compound for laboratory literature review
Doctors prescribed this medicine to patients who suffer from vitamin B12 deficiency, peripheral neuropathy, megaloblastic anemia, and neurological disorders
A vial left on a counter for three hours during multi-dose preparation has already lost 2535% of its biological activity
Less supported scenario: If your B12 status is already normal, extra B12 has not been shown to consistently boost energy in otherwise healthy people